Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
Part of paid clinical trials in Chino, California.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT01769378
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — DRUGAdministered SQ
- Dulaglutide — DRUGAdministered SQ
- Glimepiride — DRUGAdministered PO
Study Details
The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.
Key Dates
- First listed
- Jan 16, 2013
- Start date
- Jan 31, 2013
- Status verified
- Dec 2015
- Primary completion
- Dec 31, 2014
- Completion
- Dec 31, 2014
Study Design
- Enrollment
- 300 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboPlacebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
- Experimental: DulaglutideDulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
Primary Outcome Measure
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks [ Time Frame: Baseline, 24 Weeks ]
Locations (6)
Find similar trials in Chino, CA
By condition
By specialty
By research site
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Chino, CAFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Miami, FLFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· St Louis, MOFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Trenton, NJFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· The Bronx, NYFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Beaver, PA
Related Studies
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePHASE3 · Recruiting · Prokidney · Huntsville, Alabama
- An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world ConditionsRecruiting · Bayer · Multiple Locations, New Jersey
- The GRoceries Aimed at Increasing Nutrition StudyRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Continued Access to the Endogenex System for Participants in the ReCET Pivotal StudyEnrolling By Invitation · Endogenex, Inc. · Birmingham, Alabama